BR112013008749A2 - análogos de ciclosporina - Google Patents

análogos de ciclosporina

Info

Publication number
BR112013008749A2
BR112013008749A2 BR112013008749A BR112013008749A BR112013008749A2 BR 112013008749 A2 BR112013008749 A2 BR 112013008749A2 BR 112013008749 A BR112013008749 A BR 112013008749A BR 112013008749 A BR112013008749 A BR 112013008749A BR 112013008749 A2 BR112013008749 A2 BR 112013008749A2
Authority
BR
Brazil
Prior art keywords
cyclosporine analogs
cyclosporine
analogs
conditions
methods
Prior art date
Application number
BR112013008749A
Other languages
English (en)
Portuguese (pt)
Inventor
S Schaumburg Christopher
Arthur Scowen David
E Garst Michael
E Stern Michael
Robert Carling William
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112013008749A2 publication Critical patent/BR112013008749A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013008749A 2010-10-12 2011-10-11 análogos de ciclosporina BR112013008749A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39245110P 2010-10-12 2010-10-12
PCT/US2011/055788 WO2012051193A1 (en) 2010-10-12 2011-10-11 Cyclosporin analogs

Publications (1)

Publication Number Publication Date
BR112013008749A2 true BR112013008749A2 (pt) 2019-09-24

Family

ID=44883796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013008749A BR112013008749A2 (pt) 2010-10-12 2011-10-11 análogos de ciclosporina

Country Status (12)

Country Link
US (2) US9175042B2 (enExample)
EP (1) EP2627663B1 (enExample)
JP (1) JP5805773B2 (enExample)
KR (1) KR20140026328A (enExample)
CN (1) CN103261212A (enExample)
AU (1) AU2011316689B2 (enExample)
BR (1) BR112013008749A2 (enExample)
CA (1) CA2814191A1 (enExample)
IL (1) IL225616A0 (enExample)
MX (1) MX2013004062A (enExample)
RU (1) RU2013120927A (enExample)
WO (1) WO2012051193A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100305047A1 (en) * 2009-05-27 2010-12-02 Allergan, Inc. Cyclosporin derivatives for enhancing the growth of hair
PL2651965T3 (pl) * 2010-12-15 2019-04-30 Contravir Pharmaceuticals Inc Cząsteczki analogów cyklosporyny modyfikowane w aminokwasach 1 i 3
AU2013267435B2 (en) 2012-06-01 2017-11-09 Allergan, Inc. Cyclosporin A analogs
WO2014138437A1 (en) 2013-03-08 2014-09-12 Allergan, Inc. Steroid conjugates
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3046023A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) * 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
CA2334730C (en) 1998-06-12 2009-09-29 C-Chem Ag Novel cyclosporins
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
CN100478025C (zh) * 2005-03-25 2009-04-15 中国科学院上海药物研究所 一种环孢菌素a眼用微乳制剂及其制备方法
CA2652662C (en) * 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
BRPI0811538A2 (pt) 2007-05-04 2015-08-11 Allergan Inc Uso de ciclosporinas no tratamento de pacientes com lentes intraoculares.
JP5661035B2 (ja) 2008-07-10 2015-01-28 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼および皮膚の疾患および症状の治療用のシクロスポリン誘導体
CN103153329A (zh) * 2010-07-16 2013-06-12 美国科技环球有限公司 新颖的环孢霉素a衍生物在病毒感染的治疗和预防中的应用
WO2012021796A2 (en) * 2010-08-12 2012-02-16 S&T Global, Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
BR112013008864A2 (pt) 2010-10-12 2016-06-28 Allergan Inc análogos d ciclosporina
AU2011336266B2 (en) 2010-12-03 2017-04-06 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof

Also Published As

Publication number Publication date
JP5805773B2 (ja) 2015-11-10
RU2013120927A (ru) 2014-11-20
MX2013004062A (es) 2013-07-22
US20160022765A1 (en) 2016-01-28
AU2011316689B2 (en) 2016-07-14
EP2627663A1 (en) 2013-08-21
EP2627663B1 (en) 2018-02-21
US9175042B2 (en) 2015-11-03
US20120135939A1 (en) 2012-05-31
CA2814191A1 (en) 2012-04-19
KR20140026328A (ko) 2014-03-05
WO2012051193A1 (en) 2012-04-19
CN103261212A (zh) 2013-08-21
US9561259B2 (en) 2017-02-07
JP2013544786A (ja) 2013-12-19
AU2011316689A1 (en) 2013-05-02
IL225616A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
BR112013008749A2 (pt) análogos de ciclosporina
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
CO7151535A2 (es) Evento de maiz mon 87411
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
BR112012024312A2 (pt) anticorpos biespecíficos
UY34811A (es) Compuestos y composiciones para inhibir la actividad de la abl1, abl2 y bcr-abl1
UY35210A (es) Inhibidores de autotaxina
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
MX374399B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
UY34697A (es) Métodos para preparar análogos de nucleótidos
MX2018009553A (es) Metodos de seleccion.
BR112014005744A2 (pt) composições de peptídeo glucagon-like-2 e métodos para sua produção e utilização
MX391043B (es) Formulaciones de anticuerpo y metodos.
UY34210A (es) Composiciones, métodos y sistemas para la micropropagación de plantas
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
MY173521A (en) Trpv4 antagonists
WO2012129341A3 (en) Disease detection in plants
EA201591451A1 (ru) Модуляторы flap
BR112014025041B8 (pt) Composição farmacêutica
BR112014017673A8 (pt) Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112015014453A2 (pt) produtos de cuidado oral compreendendo cloreto de zinco tetrabásico e trimetilglicina
EA201491609A1 (ru) Модуляторы x рецепторов печени
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
UY33938A (es) Artículo para fumar que incluye dos o más segmentos de filtro

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.